29.03.2016 • NewsDede Willamslicensing agreementbiocontrol

Valent BioSciences, Lidochem in Technology Pact

Valent BioSciences (VBC) and Lidochem have signed a global licensing agreement for a novel, patented biocontrol technology for use in corn, soybean, and other crops.

Based on a “unique strain” of the beneficial soil microorganism Bacillus amyloliquefaciens, the technology will be developed by VBC in collaboration with Valent USA Corporation.

The two US companies based at Libertyville, Illinois, and Walnut Creek, California, respectively, are wholly-owned subsidiaries of Japan’s Sumitomo Chemical, a specialist in conventional plant protection and biorational technologies for agriculture.

The end-product will be marketed initially on the US market by Valent USA as a biological nematode seed treatment. Registration by the US Environmental Protection Agency (EPA) is expected this year, the companies said.

In future, VBC plans to focus on new formulations and expansions of the technology into other applications, crops, and regions.

“This agreement brings another important and innovative biorational technology to our growing platform for soil-based innovation,” said Ted Melnik, executive vice president and chief operating officer of VBC. “The unique mode of action of the product brings growers a potent and valuable tool in their battle against soilborne pests,” he added.

Don Pucillo, CEO of Hazlet, New Jersey-based LidoChem, said the agreement with VBC delivers on a key performance goal for the product.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.